



CLAIMS

Priority
1. 2-Aminotetralines having formula (I)



(I)

or their pharmacologically acceptable salts having formula (II)



(II)

20 wherein:

R and R₁ are independently, halogen; hydroxy; C1-C4 alkoxy, optionally substituted in position ω with groups OH, NH₂,

AMENDED SHEET

~~NR₃R₄~~ wherein R₃ and R₄ are independently H, C1-C4 alkyl, unsubstituted or substituted in position ω with groups OH, NH₂; C1-C4 alkanoyl; C1-C4 alkyl; carbamoyl; carbamoyloxy; amino; amino substituted NR₃R₄, where R₃ and R₄ have the aforesaid meanings;

R₂ is hydrogen; halogen; hydroxy; methoxy, with the proviso that the case is excluded in which the 2-aminotetraline is a raceme in which (a) R=R₁=CH₃O; OH; R₂=H; or (b) R=F; R₁=CH₃O; OH; R₂=H; and

X⁻ is the monovalent anion of a pharmacologically acceptable acid.

2. Compound according to claim 1, wherein the monovalent anion of a pharmacologically acceptable acid is selected from chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

3. A compound according to claim 1 which is selected from:

S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride

(ST 1237);

R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride

(ST 1238);

(R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride

(ST 1269);

(R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride

(ST 1275);

(R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride

(ST 1267);

(R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride

(ST 1274);

(R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride

(ST 1262).

- 10 4. An orally or parenterally administrable pharmaceutical composition containing a compound of formula I or II and a pharmaceutically acceptable carrier and/or diluent.
- 15 5. An orally or parenterally administrable pharmaceutical composition for the prevention and therapeutical treatment of inflammatory and/or autoimmune pathologies induced by inflammatory cytokines, and which comprises as active ingredient a compound according to claim 1, 2 or 3 and a pharmacologically acceptable excipient.
- 20 6. Composition according to claim 5, for the prophylactic and the therapeutical treatment of septic shock.

AMENDED SHEET

.1.

7. Composition according to claim 5, for preparing a medicament for the therapeutic treatment of rheumatoid arthritis, pancreatitis, inflammatory bowel disease, systemic lupus erythematosus, glomerulonephritis and encephalomyelitis.

ANSWER SHEET